

PHARMACOMETRIC MODELING ANALYSIS REPORT

Report Number:	PopPK-001
Report Title:	PopPK Report Title
Study Drug:	Drug A
Indication(s):	Disease X
Study Number(s):	ABC-12345
Sponsor:	ISoP Standards and Best Practices Working Group
Prepared By:	PB, MMJ, AR
Reviewed By:	PB, MMJ, AR
Approved By:	PB, MMJ, AR
Report Date:	03 Nov 2024
Report Status:	DRAFT

CONFIDENTIAL

This is a Company Name. document that contains confidential information. It is intended solely for the recipient and must not be disclosed to any other party. This material may be used only for evaluating or conducting clinical investigations; any other proposed use requires written consent from Company Name.

Table of Contents

GLOSSARY OF ABBREVIATIONS AND DEFINITIONS OF TERMS	5
1 EXECUTIVE SUMMARY	6
2 INTRODUCTION	7
3 OBJECTIVES	8
4 DATA	9
4.1 Description of Studies	9
4.2 Bioanalytical Methods	9
4.3 Analysis Datasets	9
4.3.1 Analysis Population	9
4.3.2 Handling of Missing Data and Limit of Quantifications	9
5 MATERIALS AND METHODS	10
5.1 Model Development	10
5.1.1 Structural Model	10
5.1.2 Covariate Model	10
5.1.3 Estimation Methods	10
5.1.4 Model Evaluation	10
5.1.5 Sensitivity and Simulation Analyses	10
6 RESULTS	11
6.1 Exploratory Data Analysis	11
6.2 Model Development	11
6.2.1 Base Model	11
6.2.2 Covariate Model	11
6.2.3 Final Model	11
6.3 Model Evaluation	11
6.4 Model Application	11
6.4.1 Covariate Analysis	11
7 DISCUSSION	12
8 CONCLUSION	13
9 REFERENCES	14
10 APPENDICES	15
11 TIPS	16

List of Figures

List of Tables

GLOSSARY OF ABBREVIATIONS AND DEFINITIONS OF TERMS

PK pharmacokinetic(s).

1 EXECUTIVE SUMMARY

The executive summary provides a brief overview of the analysis, highlighting the purpose, key findings affecting usage, labeling, and any additional recommendations based on the population PK analysis. It should be concise, typically consisting of 2-3 short paragraphs, and prepared with the understanding that it may be copied and pasted into a regulatory document.

2 INTRODUCTION

Provide background information about the drug being analyzed and the role of the population PK analysis in the overall clinical development program. Highlight the relevance of the drug's pharmacokinetic characteristics to the model development. Describe how the analysis aligns with the objectives of the clinical development plan and any special considerations pertinent to the study population or methodology.

3 OBJECTIVES

Clearly state the primary and secondary goals of the analysis. Define the key questions the model seeks to answer (e.g., characterizing drug exposure, identifying significant covariates). Highlight any specific hypotheses to be tested and the intended application of the model (e.g., informing dosing recommendations or understanding variability across patient subgroups).

4 DATA

4.1 Description of Studies

Provide an overview of the clinical studies included in the analysis, highlighting population, dosing regimen, sampling schedule, and study objectives.

4.2 Bioanalytical Methods

Detail the assays used to measure drug concentrations, including the type of assay, validation parameters, and limits of quantification for each study.

4.3 Analysis Datasets

4.3.1 Analysis Population

Describe the inclusion and exclusion criteria for the analysis population, with a summary of subject counts and data used across studies.

4.3.2 Handling of Missing Data and Limit of Quantifications

Explain the approach for handling missing covariates, dose, and PK samples. Describe how data below the limit of quantification (LOQ) were flagged, excluded, or imputed.

5 MATERIALS AND METHODS

5.1 Model Development

5.1.1 Structural Model

Describe the process for selecting the structural model. Include considerations such as the choice between one- and two-compartment models, linear vs. non-linear clearance, and the rationale behind these decisions. Specify the residual error model selected (e.g., additive, proportional, or combined) and the approach for modeling inter-individual variability (IIV).

5.1.2 Covariate Model

Outline the strategy for identifying and testing covariate effects on pharmacokinetic parameters. Mention the types of covariates explored (e.g., body weight, renal function) and justify their inclusion based on clinical, biological, or pharmacological relevance. Describe the covariate selection method (e.g., stepwise inclusion/exclusion, full model approach) and specify the statistical criteria used (e.g., change in objective function value).

5.1.3 Estimation Methods

Report the software used for the analysis (e.g., NONMEM, Monolix) along with the version and operating system. Detail the estimation approach (e.g., FOCE, Bayesian estimation) and describe any transformations applied to the parameters (e.g., log transformations for variability parameters).

5.1.4 Model Evaluation

Summarize the evaluation framework to assess model adequacy. Mention the diagnostic criteria (e.g., goodness-of-fit plots, residual analysis) and statistical tests (e.g., likelihood ratio test) used to select the final model. Indicate the strategies used to avoid overfitting (e.g., shrinkage metrics, cross-validation).

5.1.5 Sensitivity and Simulation Analyses

Explain the use of sensitivity analyses to evaluate the robustness of model predictions. Describe any simulations performed to predict outcomes under different dosing regimens or clinical scenarios, with the aim of supporting clinical recommendations.

6 RESULTS

6.1 Exploratory Data Analysis

Summarize key characteristics of the dataset, including subject counts, time-concentration profiles, covariate distributions, and outliers. Present relevant tables and figures to support findings.

6.2 Model Development

6.2.1 Base Model

Describe the initial structural model(s) tested, including assumptions and selection criteria. Report key parameters (e.g., compartment models, error structures) and highlight major model refinements.

6.2.2 Covariate Model

Summarize covariate selection and analysis steps. Describe relationships between covariates and PK parameters, with forward inclusion/backward elimination results and objective function value (OFV) changes.

6.2.3 Final Model

Present the final parameter estimates with their uncertainty (e.g., standard errors, confidence intervals, CV%). Describe any centering or scaling of covariates used. Provide a comparison between the base and final models.

6.3 Model Evaluation

Evaluate model performance using diagnostic plots (e.g., goodness-of-fit, prediction-corrected VPCs). Report shrinkage and other diagnostic metrics. Include stratified results by key covariates if applicable.

6.4 Model Application

6.4.1 Covariate Analysis

Describe the impact of covariates on model predictions and drug exposure. Present simulations or predictions under varying conditions (e.g., alternative dosing regimens, special populations).

7 DISCUSSION

This section provides an interpretation of the modeling results, focusing on their adequacy, clinical relevance, and impact on dosing strategies.

- **Interpretation and Model Adequacy:** *Assess whether the data and model sufficiently support conclusions and recommendations. Discuss the rationale for the modeling approach, including key assumptions and uncertainties.*
- **Comparison with Previous Analyses:** *Address consistency or discrepancies with prior population PK analyses, clinical pharmacology studies, or related investigations.*
- **Clinical Relevance:** *Evaluate the physiological and clinical significance of identified covariate relationships.*
- **Dosing Strategies and E-R Analysis:** *Summarize the evaluation of alternative dosing regimens, with a focus on safety and efficacy outcomes.*

8 CONCLUSION

A concise summary of key findings and their implications, written in plain language.

- **Major Findings:** *Summarize the primary outcomes of the analysis, including the identified relationships and model performance.*
- **Clinical Implications:** *Highlight how the findings support dosing recommendations, safety, or efficacy decisions.*
- **Future Considerations:** *Identify any potential areas for further study or refinement of the model if needed.*

9 REFERENCES

Provide all cited sources used in the report in a consistent and appropriate style.

ICON Development Solutions. 2024. "NONMEM." <https://www.iconplc.com/innovation/nonmem/>.

Lixoft. 2024. "Monolix Suite." Simulations Plus. <https://lixoft.com/products/monolix/>.

Posit Software, PBC. 2024. "Quarto." <https://quarto.org>.

10 APPENDICES

The Appendix contains supplemental materials that provide additional context and support for the analysis, cross-referenced as needed within the main report.

- **Supplemental Tables and Figures** *Summaries and analyses that support model development or conclusions, but are not central to the report.*
- **Run Record** *Detailed steps and decisions made during model development.*
- **Methods and Code Documentation** *Methods and scripts used to generate key figures and tables (preferably submitted separately).*
- **Sample Removal List** *Details of excluded samples with reasons for removal.*
- **Data Flow Diagram** *Visual representation of the relationships between input datasets, codes/control streams, and output datasets in the analysis.*
- **Model Input and Output Files** *Provide input and output files (e.g., NONMEM) relevant to the base and final models.*

11 TIPS

This section provides brief information on certain aspects of the report template, such as how to use abbreviations, references, etc

Abbreviations:

*Abbreviations can be used throughout the report. The **gls** command can be used to define abbreviations in the text. For example, `\gls{PK}` will be replaced with **Pharmacokinetics (PK)** in the text the first time its used and **PK** for subsequent uses. The **glspl** command can be used to define plural abbreviations. For example, `\glspl{PK}` will be replaced with **Pharmacokinetics (PKs)**.*

- *First Use:* pharmacokinetic(s) (PK)
- *Second Use:* PK

References:

*References can be cited in the text using the @ followed by the key from bibtex input.

- *Citation:*

To reference NONMEM @NONMEM {ICON Development Solutions (2024)} or Monolix @Monolix {Lixoft (2024)} or Quarto @Quarto {Posit Software, PBC (2024)}